NO994760L - Vandige immunologiske adjuvanspreparat av monofosforyllipid A - Google Patents

Vandige immunologiske adjuvanspreparat av monofosforyllipid A

Info

Publication number: NO994760L
Authority: NO; Norway
Prior art keywords: surfactant; lipid; derivative; attenuated; monophosphoryl lipid
Prior art date: 1997-04-01

Application number

NO994760A

Other languages

English (en)

Norwegian (no)

Other versions

NO994760D0 (no

Inventor

Thomas R Crane

Original Assignee

Ribi Immunochem Research Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-01

Filing date

1999-09-30

Publication date

1999-11-26

1999-09-30 Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc

1999-09-30 Publication of NO994760D0 publication Critical patent/NO994760D0/no

1999-11-26 Publication of NO994760L publication Critical patent/NO994760L/no

Links

229940035032 monophosphoryl lipid a Drugs 0.000 title abstract 3
239000000568 immunological adjuvant Substances 0.000 title 1
238000002360 preparation method Methods 0.000 title 1
239000004094 surface-active agent Substances 0.000 abstract 7
239000000203 mixture Substances 0.000 abstract 6
230000002238 attenuated effect Effects 0.000 abstract 4
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical class O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 abstract 4
239000002671 adjuvant Substances 0.000 abstract 3
102000036639 antigens Human genes 0.000 abstract 3
108091007433 antigens Proteins 0.000 abstract 3
241001465754 Metazoa Species 0.000 abstract 2
239000000427 antigen Substances 0.000 abstract 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 abstract 1
230000005875 antibody response Effects 0.000 abstract 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
210000004698 lymphocyte Anatomy 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
230000002062 proliferating effect Effects 0.000 abstract 1
230000004044 response Effects 0.000 abstract 1
210000002966 serum Anatomy 0.000 abstract 1
239000002904 solvent Substances 0.000 abstract 1
239000000725 suspension Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
- C07H13/06—Fatty acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Mycology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

NO994760A 1997-04-01 1999-09-30 Vandige immunologiske adjuvanspreparat av monofosforyllipid A NO994760L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US83107397A	1997-04-01	1997-04-01
PCT/US1998/006528 WO1998043670A2 (en)	1997-04-01	1998-04-01	Aqueous immunologic adjuvant compositions of monophosphoryl lipid a

Publications (2)

Publication Number	Publication Date
NO994760D0 NO994760D0 (no)	1999-09-30
NO994760L true NO994760L (no)	1999-11-26

Family

ID=25258229

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO994760A NO994760L (no)	1997-04-01	1999-09-30	Vandige immunologiske adjuvanspreparat av monofosforyllipid A

Country Status (18)

Country	Link
EP (1)	EP0971739B1 (pt)
JP (1)	JP5019494B2 (pt)
KR (1)	KR100603884B1 (pt)
CN (2)	CN1326564C (pt)
AT (1)	ATE278419T1 (pt)
AU (1)	AU743114B2 (pt)
BR (1)	BR9811262A (pt)
CA (1)	CA2284586C (pt)
DE (1)	DE69826842T2 (pt)
ES (1)	ES2227825T3 (pt)
HU (1)	HUP0001403A3 (pt)
IL (2)	IL132126A0 (pt)
NO (1)	NO994760L (pt)
NZ (1)	NZ338101A (pt)
PL (1)	PL190237B1 (pt)
PT (1)	PT971739E (pt)
TR (1)	TR199902437T2 (pt)
WO (1)	WO1998043670A2 (pt)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6491919B2 (en)	1997-04-01	2002-12-10	Corixa Corporation	Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
GB9706957D0 (en)	1997-04-05	1997-05-21	Smithkline Beecham Plc	Formulation
GB9820525D0 (en)	1998-09-21	1998-11-11	Allergy Therapeutics Ltd	Formulation
GB0000891D0 (en) *	2000-01-14	2000-03-08	Allergy Therapeutics Ltd	Formulation
PT1326638E (pt)	2000-10-18	2008-02-06	Glaxosmithkline Biolog Sa	Vacinas contra cancros
ATE503493T1 (de)	2001-02-23	2011-04-15	Glaxosmithkline Biolog Sa	Influenza vakzinzusammensetzungen zur intradermaler verabreichung
US20030031684A1 (en)	2001-03-30	2003-02-13	Corixa Corporation	Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
GB0109297D0 (en)	2001-04-12	2001-05-30	Glaxosmithkline Biolog Sa	Vaccine
TWI228420B (en)	2001-05-30	2005-03-01	Smithkline Beecham Pharma Gmbh	Novel vaccine composition
US20100221284A1 (en)	2001-05-30	2010-09-02	Saech-Sisches Serumwerk Dresden	Novel vaccine composition
GB0321615D0 (en)	2003-09-15	2003-10-15	Glaxo Group Ltd	Improvements in vaccination
ES2493440T3 (es) *	2004-12-17	2014-09-11	De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport	Desacilación de LPS en bacterias Gram negativas
GB0503337D0 (en)	2005-02-17	2005-03-23	Glaxosmithkline Biolog Sa	Compositions
GB0504436D0 (en)	2005-03-03	2005-04-06	Glaxosmithkline Biolog Sa	Vaccine
KR20120089475A (ko)	2005-04-29	2012-08-10	인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이)	결핵균 감염을 예방 또는 치료하기 위한 신규한 방법
PL1909830T3 (pl) *	2005-08-02	2012-02-29	Novartis Vaccines And Diagnostics S R L	Ograniczenie oddziaływania pomiędzy olejem w adiuwancie a środkiem powierzchniowo czynnym w antygenie
TWI457133B (zh) *	2005-12-13	2014-10-21	Glaxosmithkline Biolog Sa	新穎組合物
US8018440B2 (en)	2005-12-30	2011-09-13	Microsoft Corporation	Unintentional touch rejection
US20090181078A1 (en)	2006-09-26	2009-07-16	Infectious Disease Research Institute	Vaccine composition containing synthetic adjuvant
EP2484375B1 (en)	2006-09-26	2018-05-23	Infectious Disease Research Institute	Vaccine composition containing synthetic adjuvant
US8836648B2 (en)	2009-05-27	2014-09-16	Microsoft Corporation	Touch pull-in gesture
RU2732574C2 (ru)	2009-06-05	2020-09-21	Инфекшес Дизиз Рисерч Инститьют	Синтетические глюкопиранозиллипидные адъюванты
FR2954703B1 (fr)	2009-12-28	2013-12-13	Chu Nantes	Agonistes des recepteurs tlr 4 et 9 pour prevenir les complications septiques de l'immunodepression post-traumatique chez les patients hospitalises pour traumatismes severes
US8261213B2 (en)	2010-01-28	2012-09-04	Microsoft Corporation	Brush, carbon-copy, and fill gestures
US9411504B2 (en)	2010-01-28	2016-08-09	Microsoft Technology Licensing, Llc	Copy and staple gestures
US9519356B2 (en)	2010-02-04	2016-12-13	Microsoft Technology Licensing, Llc	Link gestures
US9310994B2 (en)	2010-02-19	2016-04-12	Microsoft Technology Licensing, Llc	Use of bezel as an input mechanism
US8799827B2 (en)	2010-02-19	2014-08-05	Microsoft Corporation	Page manipulations using on and off-screen gestures
US9367205B2 (en)	2010-02-19	2016-06-14	Microsoft Technolgoy Licensing, Llc	Radial menus with bezel gestures
US9454304B2 (en)	2010-02-25	2016-09-27	Microsoft Technology Licensing, Llc	Multi-screen dual tap gesture
US8707174B2 (en)	2010-02-25	2014-04-22	Microsoft Corporation	Multi-screen hold and page-flip gesture
US9075522B2 (en)	2010-02-25	2015-07-07	Microsoft Technology Licensing, Llc	Multi-screen bookmark hold gesture
US8751970B2 (en)	2010-02-25	2014-06-10	Microsoft Corporation	Multi-screen synchronous slide gesture
US8612874B2 (en)	2010-12-23	2013-12-17	Microsoft Corporation	Presenting an application change through a tile
US8689123B2 (en)	2010-12-23	2014-04-01	Microsoft Corporation	Application reporting in an application-selectable user interface
US9423951B2 (en)	2010-12-31	2016-08-23	Microsoft Technology Licensing, Llc	Content-based snap point
US9383917B2 (en)	2011-03-28	2016-07-05	Microsoft Technology Licensing, Llc	Predictive tiling
GB201106357D0 (en)	2011-04-14	2011-06-01	Pessi Antonello	Composition and uses thereof
MX350795B (es)	2011-04-08	2017-09-19	Inmune Design Corp	Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares.
US9104440B2 (en)	2011-05-27	2015-08-11	Microsoft Technology Licensing, Llc	Multi-application environment
US9158445B2 (en)	2011-05-27	2015-10-13	Microsoft Technology Licensing, Llc	Managing an immersive interface in a multi-application immersive environment
US9658766B2 (en)	2011-05-27	2017-05-23	Microsoft Technology Licensing, Llc	Edge gesture
US9104307B2 (en)	2011-05-27	2015-08-11	Microsoft Technology Licensing, Llc	Multi-application environment
US9557909B2 (en)	2011-09-09	2017-01-31	Microsoft Technology Licensing, Llc	Semantic zoom linguistic helpers
US9146670B2 (en)	2011-09-10	2015-09-29	Microsoft Technology Licensing, Llc	Progressively indicating new content in an application-selectable user interface
US9244802B2 (en)	2011-09-10	2016-01-26	Microsoft Technology Licensing, Llc	Resource user interface
AU2012308149A1 (en)	2011-09-12	2014-03-27	Sheena Mary Geraldine MCCORMACK	Methods and compositions for raising an immune response to HIV
DK2850431T3 (en)	2012-05-16	2018-07-16	Immune Design Corp	Vaccines against HSV-2
EP2666785A1 (en)	2012-05-23	2013-11-27	Affiris AG	Complement component C5a-based vaccine
EP2703483A1 (en)	2012-08-29	2014-03-05	Affiris AG	PCSK9 peptide vaccine
WO2014043189A1 (en)	2012-09-14	2014-03-20	The Regents Of The University Of Colorado, A Body Corporate	Conditionally replication deficient herpes viruses and use thereof in vaccines
US9582122B2 (en)	2012-11-12	2017-02-28	Microsoft Technology Licensing, Llc	Touch-sensitive bezel techniques
EA032326B1 (ru)	2013-04-18	2019-05-31	Иммьюн Дизайн Корп.	Монотерапия gla для применения в лечении рака
US9463198B2 (en)	2013-06-04	2016-10-11	Infectious Disease Research Institute	Compositions and methods for reducing or preventing metastasis
US9477337B2 (en)	2014-03-14	2016-10-25	Microsoft Technology Licensing, Llc	Conductive trace routing for display and bezel sensors
HUE047808T2 (hu) *	2014-03-26	2020-05-28	Glaxosmithkline Biologicals Sa	Mutáns Staphylococcus antigének
US10759836B2 (en)	2014-07-18	2020-09-01	University Of Washington	Cancer vaccine compositions and methods of use thereof
EP3138579A1 (en)	2015-09-05	2017-03-08	Biomay Ag	Fusion protein for use in the treatment of a hepatitis b virus infection
GB201614799D0 (en)	2016-09-01	2016-10-19	Glaxosmithkline Biologicals Sa	Compositions
EP3295956A1 (en)	2016-09-20	2018-03-21	Biomay Ag	Polypeptide construct comprising fragments of allergens
AU2018330165B2 (en)	2017-09-08	2025-07-17	Access To Advanced Health Institute	Liposomal formulations comprising saponin and methods of use
US20190275134A1 (en)	2018-03-12	2019-09-12	Janssen Pharmaceuticals, Inc	Vaccines against urinary tract infections
EP3569612A1 (en)	2018-05-18	2019-11-20	Biomay Ag	Treatment and prevention of house dust mite allergies
JOP20210256A1 (ar)	2019-03-18	2023-01-30	Janssen Pharmaceuticals Inc	متقارن حيوي لعديدات سكاريد المستضدات-o للإشريكية القولونية، طرائق إنتاجه، وطرائق استخدامه
KR102574882B1 (ko)	2019-03-18	2023-09-04	얀센 파마슈티칼즈, 인코포레이티드	대장균 o-항원 다당류의 바이오컨쥬게이트의 생성 방법, 이의 조성물 및 이의 사용 방법
US20220362368A1 (en)	2019-10-02	2022-11-17	Janssen Vaccines & Prevention B.V.	Staphylococcus peptides and methods of use
JP7485771B2 (ja)	2020-01-16	2024-05-16	ヤンセンファーマシューティカルズ，インコーポレーテッド	ＦｉｍＨ変異体、その組成物、及びその使用
PH12023550020A1 (en)	2020-09-17	2024-03-11	Janssen Pharmaceuticals Inc	Multivalent vaccine compositions and uses thereof
KR102746713B1 (ko)	2021-01-12	2024-12-24	얀센 파마슈티칼즈, 인코포레이티드	FimH 돌연변이체, 이를 포함하는 조성물 및 이의 용도
KR20230164108A (ko)	2021-04-01	2023-12-01	얀센 파마슈티칼즈, 인코포레이티드	E. coli O18 생물접합체의 생산
EP4346896A4 (en) *	2021-05-27	2025-04-02	Revelation Biosciences, Inc.	Mpla compositions and methods of use
CN121221758A (zh) *	2025-12-02	2025-12-30	华诺泰生物医药科技(成都)有限公司	一种即用型稳定3d-mla佐剂溶液的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4912094B1 (en) *	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
US5068191A (en) *	1989-08-31	1991-11-26	The Biomembrane Institute	Purified histo-blood group a glycosyltransferase and antibodies thereto
US5552141A (en) *	1991-10-30	1996-09-03	Ribi; Hans O.	Polymeric immunological adjuvants
US5776468A (en) *	1993-03-23	1998-07-07	Smithkline Beecham Biologicals (S.A.)	Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A

1998
- 1998-04-01 AT AT98915239T patent/ATE278419T1/de active
- 1998-04-01 ES ES98915239T patent/ES2227825T3/es not_active Expired - Lifetime
- 1998-04-01 NZ NZ338101A patent/NZ338101A/en unknown
- 1998-04-01 CN CNB2004100713486A patent/CN1326564C/zh not_active Expired - Fee Related
- 1998-04-01 PT PT98915239T patent/PT971739E/pt unknown
- 1998-04-01 TR TR1999/02437T patent/TR199902437T2/xx unknown
- 1998-04-01 JP JP54200198A patent/JP5019494B2/ja not_active Expired - Lifetime
- 1998-04-01 PL PL98336698A patent/PL190237B1/pl not_active IP Right Cessation
- 1998-04-01 EP EP98915239A patent/EP0971739B1/en not_active Expired - Lifetime
- 1998-04-01 CN CN98804685A patent/CN1259052A/zh active Pending
- 1998-04-01 WO PCT/US1998/006528 patent/WO1998043670A2/en not_active Ceased
- 1998-04-01 CA CA2284586A patent/CA2284586C/en not_active Expired - Lifetime
- 1998-04-01 IL IL13212698A patent/IL132126A0/xx active IP Right Grant
- 1998-04-01 BR BR9811262-7A patent/BR9811262A/pt not_active Application Discontinuation
- 1998-04-01 KR KR1019997008958A patent/KR100603884B1/ko not_active Expired - Fee Related
- 1998-04-01 HU HU0001403A patent/HUP0001403A3/hu unknown
- 1998-04-01 DE DE69826842T patent/DE69826842T2/de not_active Expired - Lifetime
- 1998-04-01 AU AU69473/98A patent/AU743114B2/en not_active Ceased
1999
- 1999-09-29 IL IL132126A patent/IL132126A/en not_active IP Right Cessation
- 1999-09-30 NO NO994760A patent/NO994760L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP0971739B1 (en)	2004-10-06
IL132126A0 (en)	2001-03-19
TR199902437T2 (xx)	2000-01-21
CN1326564C (zh)	2007-07-18
WO1998043670A2 (en)	1998-10-08
BR9811262A (pt)	2000-10-17
JP2001526640A (ja)	2001-12-18
CN1259052A (zh)	2000-07-05
HUP0001403A3 (en)	2003-05-28
CA2284586A1 (en)	1998-10-08
EP0971739A2 (en)	2000-01-19
KR100603884B1 (ko)	2006-07-24
IL132126A (en)	2006-10-05
WO1998043670A3 (en)	1998-12-30
HK1026613A1 (en)	2000-12-22
AU6947398A (en)	1998-10-22
CA2284586C (en)	2011-02-08
AU743114B2 (en)	2002-01-17
HUP0001403A2 (hu)	2000-09-28
ATE278419T1 (de)	2004-10-15
PL336698A1 (en)	2000-07-03
KR20010005882A (ko)	2001-01-15
ES2227825T3 (es)	2005-04-01
PL190237B1 (pl)	2005-11-30
CN1575815A (zh)	2005-02-09
DE69826842T2 (de)	2005-11-24
DE69826842D1 (de)	2004-11-11
NZ338101A (en)	2002-03-28
PT971739E (pt)	2004-12-31
JP5019494B2 (ja)	2012-09-05
NO994760D0 (no)	1999-09-30

Publication	Publication Date	Title
NO994760L (no)	1999-11-26	Vandige immunologiske adjuvanspreparat av monofosforyllipid A
DE60037514D1 (de)	2008-01-31	Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a
US6500453B2 (en)	2002-12-31	Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom
CA2279935C (en)	2009-01-20	Chelating immunostimulating complexes
JP2502234B2 (ja)	1996-05-29	リポソ―ム含有ワクチン組成物
EP0688206B1 (en)	2000-05-03	Vaccine delivery system and shelf-stable precursor solution for remote encapsulation of active ingredients
DK15087A (da)	1987-07-15	Immunogenkomplekser og deres anvendelse i laegemidler, isaer vacciner
Han et al.	1997	Application of liposomes for development of oral vaccines: study of in vitro stability of liposomes and antibody response to antigen associated with liposomes after oral immunization
JP2001523216A (ja)	2001-11-20	新規のアジュバント組成物と、それからなるワクチン製剤
US20080226709A1 (en)	2008-09-18	Phospholipid membrane preparation
WATARAI et al.	1998	Antibody response in the intestinal tract of mice orally immunized with antigen associated with liposomes
Sachetelli et al.	1999	Evaluation of the pulmonary and systemic immunogenicity of fluidosomes, a fluid liposomal–tobramycin formulation for the treatment of chronic infections in lungs
US20020031543A1 (en)	2002-03-14	Adjuvant comprising pulmonary surfactant
KR0178422B1 (ko)	1999-03-20	한탄 바이러스의 펩타이드 항원을 함유하는 리포좀
KR0173366B1 (ko)	1999-02-01	B형 간염 바이러스의 펩타이드 항원을 함유하는 리포좀
JPH08183742A (ja)	1996-07-16	経鼻ワクチンリポソーム
KR0173365B1 (ko)	1999-02-01	C형 간염 바이러스의 펩타이드 항원을 함유하는 리포좀
DE69505236T2 (de)	1999-05-20	Liposomen und deren verwendung insbesondere zur herstellung immunomodulatorischer mittel
KR100189701B1 (ko)	1999-06-01	B형 간염 바이러스의 x 단밸직 유래의 펩타이드 항원을 함유하는 리포좀
KR20030028672A (ko)	2003-04-10	폐렴구균성 표면 접착단백질의 가용화용 조성물, 가용화용액상제형, 및 가용화용 분말제형, 이들 각각의 제조방법및 백신
HK1012991B (en)	2001-03-02	Vaccine delivery system and shelf-stable precursor solution for remote encapsulation of active ingredients

Legal Events

Date	Code	Title	Description
2009-08-24	FC2A	Withdrawal, rejection or dismissal of laid open patent application
2009-09-14	FC2A	Withdrawal, rejection or dismissal of laid open patent application